Stevioside modulates oxidative damage in the liver and kidney of high fat/low streptozocin diabetic rats

Stevioside modulates oxidative damage in the liver and kidney of high fat/low streptozocin diabetic rats
复制标题

DOI:
10.1016/j.heliyon.2018.e00640
复制
发表时间:
2018-05-01
期刊:
影响因子:
4
通讯作者:
Okungbaye, Rotimi
Okungbaye, Rotimi
中科院分区:
综合性期刊4区
文献类型:
--
作者:
Rotimi, Solomon Oladapo;Rotimi, Oluwakemi Anuoluwapo;Okungbaye, Rotimi

文献摘要

被引文献

相似文献

本研究采用高脂低链脲佐菌素大鼠模型,探讨甜菊糖苷预防2型糖尿病(T2DM)肝脏和肾脏氧化DNA损伤的潜力。大鼠每天口服12.5、25和50 mg/kg甜菊糖甙,连续21 d。用分光光度法测定T2DM生物标志物、血脂和氧化应激水平。DNA阶梯分析法用于评估肝脏和肾脏的DNA片段,计算分析用于预测甜菊糖苷抗糖尿病特性的机制。甜菊苷显著(p < 0.05)降低血糖、胰岛素、二肽基肽酶IV水平和肾血管紧张素转换酶活性。甜菊苷通过降低肝脏和肾脏的脂质过氧化和一氧化氮水平显著降低氧化应激;从而降低糖尿病大鼠肝脏和肾脏DNA断裂的程度。硅分析表明,甜菊糖甙发挥这些作用的能力与其抑制β -肾上腺素能受体激酶和g蛋白偶联受体激酶有关。本研究的结果表明,预防DNA断裂可能是使用甜菊糖苷治疗2型糖尿病的另一个好处。
This study investigated the potential of stevioside to prevent oxidative DNA damage in the liver and kidney of type 2 diabetes mellitus (T2DM) using high fat-low streptozocin rat model. Rats were treated daily with 12.5, 25 and 50 mg/kg stevioside orally for 21 days. Levels of biomarkers of T2DM, lipid profile and oxidative stress were assayed spectrophotometrically. The DNA ladder assay method was used to assess DNA fragmentation in the liver and kidney while computational analysis was used to predict the mechanisms of antidiabetic properties of stevioside. Stevioside significantly (p < 0.05) decreased the levels of plasma glucose, insulin, dipeptidyl peptidase IV and activities of kidney angiotensin converting enzyme. Stevioside significantly reduced oxidative stress by decreasing the levels of lipid peroxidation and nitric oxide in the liver and kidney; thereby, reducing the extent of DNA fragmentation in the liver and kidney of the diabetic rats. The in silico analysis showed that the ability of stevioside to exert these effects is linked to its inhibition of beta-adrenergic receptor kinase and G-protein-coupled receptor kinase. The results of this study suggest that the prevention of DNA fragmentation may be an additional benefit of the use of stevioside in the management of T2DM.